M
any epidemiological studies have shown that C-reactive protein (CRP) is an important risk factor for atherosclerosis and coronary heart disease. 1 The mechanisms underlying this association are not completely clear: although CRP may merely be a nonspecific marker of inflammation, it is possible that CRP plays a direct role in the pathogenesis of inflammation/ atherosclerosis. We recently found that CRP directly induces the expression of adhesion molecules by endothelial cells. [1] [2] [3] However, the expression of specific chemokines, particularly monocyte chemoattractant protein-1 (MCP-1), also has a major role in recruiting monocytes into the vessel wall. 4 Thus, the aim of the present study was to assess the possible effects of CRP on the expression of chemokines by endothelial cells and to assess the possible role of pharmacological treatment in the modulation of this effect.
Methods

Materials
Human umbilical vein endothelial cells (HUVEC; from Cascade) were grown in M199 medium with endothelial cell growth supplement, heparin, and 15% fetal bovine serum. Cells were used at passages 2 to 4.
Recombinant human CRP and highly purified CRP from human serum were purchased from Calbiochem, and interleukin-1␤ (IL-1␤) was obtained from RandD Systems. All reagents were endotoxinfree by limulus test (from Sigma; sensitivity, 0.06 U/mL). Purity of CRP preparations was also confirmed by SDS-PAGE (single band on silver staining of overloaded gels). For inhibitory experiments, HUVEC were pretreated with various peroxisome proliferator-activated receptor (PPAR)-␥ agonists, including troglitazone (ParkeDavis), ciglitazone (Biomol), 15-deoxy-⌬12, 14 -prostaglandin J 2 (15d-PGJ2; Calbiochem); the PPAR␣ agonists fenofibrate and Wy 14649 (Sigma); the hydroxymethylglutaryl coenzyme A antagonist (statin) simvastatin; or vehicle (0.1% DMSO or PBS) at the concentrations indicated. After 2 hours, the cells were incubated with CRP or IL-1␤ 10 ng/mL for 24 hours. Simvastatin prodrug (Merck) was activated as previously described. 5 
Analysis of Conditioned Medium
Experiments were performed in HUVEC that were cultured in 12-well plates in medium CS-C with 10 mmol/L HEPES and 15% human serum (Sigma). Culture supernatants were collected 6 to 24 hours after stimulation with either IL-1␤ or CRP at the concentration indicated. The secretion of MCP-1 and RANTES was assessed by sandwich ELISA (Quantikine, by RandD Systems). All determinations were performed in duplicate. Data are expressed as meanϮSD of 5 to 6 separate experiments. Cell viability was assessed by Trypan blue exclusion.
Analysis of multiple paired data within the same experiments was performed with the nonparametric Friedman test and the Wilcoxon test (GB-STAT V6 software). PϽ0.05 (2-tailed) was considered significant.
Results
CRP Induces Expression of MCP-1 but Not RANTES in HUVEC
In a 24-hour time course study shown in the Figure (A), CRP at a concentration of 100 g/mL induced a significant secretion of MCP-1, with a maximal effect at 24 hours (a 7 fold-increase at 24 hours, Pϭ0.001). Dose-response experiments performed with 24-hour incubation showed a significant induction of MCP-1 even with 5 g/mL (from 1.1Ϯ0.5 ng/mL at baseline to 2.4Ϯ0.9 with 10 g/mL of CRP) that peaked at 100 g/mL (up to 9.7Ϯ4.8 ng/mL, Pϭ0.001; Figure, panel C). The maximal effects of CRP were similar to those observed after incubation with IL-1␤ 10 ng/mL (8.6Ϯ3.7 ng/mL, Figure, panel B). All these experiments were performed in the presence of 15% human serum. Incubation with CRP 100 g/mL did not increase MCP-1 concentrations in HUVEC cultured in serum-free medium ( Figure, panel C) , although the absence of serum did not change the response to IL-1␤.
Secretion of RANTES was not increased by incubation with CRP 100 g/mL (Figure, panel B) . Similarly, incubation with IL-1␤ 10 ng/mL did not induce RANTES expression.
Modulation of CRP Effects by Statins and PPAR Activators
The effects of pretreatment with simvastatin and several PPAR activators on the induction of MCP-1 are shown in the Table. Simvastatin 5 mol/L significantly reduced (Ϸ43% of maximal response) the secretion of MCP-1 induced by CRP. Aspirin, even at high concentrations (up to 1 mmol/L), did not inhibit the effects of CRP. The PPAR␥ activators troglitazone and ciglitazone had no significant effects at low concentrations, but they did significantly inhibit MCP-1 secretion at a high concentration (200 mol/L ciglitazone). However, 15d-PGJ2 10 mol/L almost completely abolished the induction of MCP-1 by CRP. The PPAR␣ activators fenofibrate (100 mol/L) and Wy 14649 (100 mol/L) completely inhibited the secretion of MCP-1, although a lower concentration (10 mol/L) of Wy 14649 had no effect.
Discussion
This study shows that CRP induces the expression of MCP-1 but not RANTES in HUVEC. This effect can be modulated by drugs known to inhibit chemokine expression by activated endothelial cells, such as simvastatin and PPAR activators.
CRP is strongly associated with the occurrence of new cardiovascular events in patients with both unstable 6 and stable angina, and it is an important risk factor for cardiac mortality in normal subjects. 7 The mechanism(s) of this association are still unclear. Although CRP can merely be a marker of an underlying inflammatory/atherosclerotic process, it is possible that CRP may be directly involved in the pathogenesis of atherosclerosis/inflammation. 1-3 CRP can induce the expression of tissue factor by monocytes, 8, 9 and it is present in atherosclerotic plaques but not in the normal vessel wall. 10 CRP deposits in early atherosclerotic lesions may precede the appearance of monocytes. 11 Recently, we found that CRP, at concentrations Ն5 g/mL, induces the expression of the adhesion molecules intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin in human endothelial cells. 3 The present study is the first to demonstrate a direct effect of CRP on the secretion of a specific chemokine (MCP-1) from endothelial cells. These effects are evident at CRP concentrations similar to those observed in patients at an increased risk of new coronary events 12, 13 and are close in magnitude to those observed with the proinflammatory cytokine IL-1␤. Chemokines, particularly MCP-1, play a key role in the migration of monocytes and T-cells into the vessel wall and in the evolution of atherosclerosis. 14, 15 Interestingly, neither CRP nor IL-1␤ were able to induce RANTES expression by endothelial cells. In a previous study, Effects of CRP on production of MCP-1 and RANTES in HUVEC. A, Time course of production of MCP-1 during incubation with CRP 100 g/mL. Production of MCP-1 is expressed as time increase in MCP-1 concentration compared with HUVEC incubated with human albumin 100 g/mL for the same time. B, Time course of production of RANTES during incubation with CRP 100 g/mL. C, Dose-response of the effects of 24-hour incubation with CRP on MCP-1 production; concentration of CRP is expressed in g/mL. NoS indicates incubation with CRP 100 g/mL in serum-free conditions; all other experiments were performed in presence of 15% human serum. CTRL indicates control, and the error bars indicate the SD of the mean. *PϽ0.05.
no RANTES was produced after stimulating HUVEC with IL-1␤; RANTES production was only induced by cotreatment with interferon-␥. 16 Epidemiological studies have suggested an interaction between CRP and statins 17 and aspirin treatment. 7, 18 Statins may reduce serum CRP levels 17 and mortality in patients with low cholesterol levels but high CRP concentrations. Furthermore, statins can inhibit the expression of MCP-1 induced by IL-1 in endothelial cells and monocytes. 19 In the present study, treatment with simvastatin partially inhibited the induction of MCP-1 by CRP on endothelial cells.
PPAR activators may reduce the proinflammatory effects of cytokines on vascular cells and may have beneficial effects on the progression of atherosclerosis in animal models. 20 -23 Although in a previous study low concentrations of troglitazone (10 mol/L) inhibited tumor necrosis factor-␣-induced MCP-1 expression in endothelial cells, 24 in the present study, thiazoledinediones had significant effects only at a high concentration; this concentration was much higher than their affinity for PPAR␥, although 15d-PGJ2 had significant effects at concentrations close to its K D for PPAR␥ (2.5 mol/L). However, the inhibitory effects of 15d-PGJ2 may be also due to its inhibition of nuclear factor-B by PPAR␥-independent mechanisms. 25 PPAR␣ activators, such as fenofibrate and Wy 14649, almost completely blocked the induction of MCP-1 by CRP. These anti-inflammatory effects of PPAR␣ activators may be explained, at least in part, by their inhibition of the nuclear factor-B and activator protein-1 pathways. 26 In conclusion, our study demonstrates that CRP can induce the production of MCP-1 by endothelial cells. These effects can be modulated by pharmacological interventions, particularly simvastatin and fenofibrate. Our findings support the hypothesis of a direct role of CRP in the pathogenesis of inflammation/atherosclerosis and open the way to new pharmacological strategies for its treatment. Values are meanϮSD or percentage. *PϽ0.05 vs CRP 100 g/mL alone.
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